Antex: Helicobacter pylori/Shigella und Ecoli bald Geschichte - 500 Beiträge pro Seite

[Donkosak]

Also nun unter Antex als Thema nochmal.

Es handelt sich hier um eine kleine Biotechklitsche mit einigem Potential.Kopiere mal die Produkte rein.

>>> New Clinical Development Search

Clinical Development for Antex Biologics
Tradename Developer(s) Partners Indications Current Phase
ACTIVAX Antex Biologics
United States Department of Defense
Diarrhea
I
Campyvax Antex Biologics
GlaxoSmithKline
none Gastrointestinal Disorder (misc)
II
GONOVAX Antex Biologics
none Gonorrhea
Pre-Clinical
Haemophilus Influenzae Vaccine Antex Biologics
Aventis Pasteur
Aventis S.A.
none Otitis media (middle ear infection)
I
HELIVAX Antex Biologics
none Gastric cancer
H. Pylori (induced peptic ulcer)
I
TRACVAX Antex Biologics
none Chlamydia trachomatis
Pre-Clinical

Wirklich gut hierbei ist die Therapie des Helicbacter(normale Standarttherapie mit einem Protonenpumpenhemmer und Antibiotika sehr teuer und die Complience das Patienten oft mangelhaft)
Und die Reisediarhoen die ein Ärgernis für jeden Reisenden sind.Eine Impfung ,und ich wette jeder würde die bezahlen,und das Thema ist erledigt.

Also wer Lust hat zu schreiben dann los.

Donkosak-Grischka

[Donkosak]

Schön Guten Abend

Hier was "Halbneues"

Antex Reports HELIVAX Clinical Trial Results; HELIVAX Vaccine for H. pylori Progresses to Phase II Human Study
FRIDAY, NOVEMBER 09, 2001 8:59 AM
- PRNewswire

Antex Reports HELIVAX Clinical Trial Results; HELIVAX Vaccine for H. pylori Progresses to Phase II Human Study

11/9/2001 8:59:00 AM
GAITHERSBURG, Md., Nov 9, 2001 /PRNewswire via COMTEX/ -- Antex Biologics Inc. (ANX) today announced the completion of laboratory analyses of its Phase 1B clinical trial of HELIVAX(TM), the Company`s oral vaccine intended to prevent and treat gastrointestinal infections and disease caused by Helicobacter pylori. The primary objective of this second human trial was to evaluate the effect of mucosal adjuvant doses with several different vaccine formulations.

As reported earlier, all formulations and dosages were found to be safe and did not cause any adverse clinical events, and the vaccine stimulated serum, mucosal and salivary antibodies against H. pylori. The laboratory analysis of the cellular immune response and fecal antibody production has been completed. As anticipated based on the earlier reported results, the vaccinated volunteers were positive for immune cell proliferation, cytokine production and secretory IgA antibodies. These efficacy results provide the basis for proceeding to a Phase II clinical trial, which will be conducted in early 2002.

"The results of this Phase IB trial are consistent with the initial Phase IA safety trial and all pre-clinical studies," commented Dr. Vic Esposito, Chairman and CEO. "The immune response results are encouraging and provide the basis to design a Phase II clinical trial. The Phase II trial will continue to broaden our understanding of the immune response to H. pylori and will evaluate the vaccine for both prevention and eradication of H. pylori infections."

Helicobacter pylori is the most common global human pathogen; two-thirds of the world`s population is infected with this bacterium, including about approximately 50 percent of Americans. It is also recognized as the predominant cause of ulcers and is associated with stomach cancers. Helicobacter pylori is the only bacteria classified by the World Health Organization as a Type I carcinogen. The market for a prophylactic and therapeutic vaccine against Helicobacter pylori is estimated to exceed $1 billion annually.


Euer Donkosak

[kiju]

Wie konnte unsere kleine Antex eigentlich die letzten Tage so gen Süden segeln?

[Donkosak]

Hallo an Alle

Warum es gen Süden geht, keine Ahnung, aber es geht doch noch.Die nächste "wichtige" Nachricht(nicht die die ich gleich reinstelle)wird dem Kurs schon wieder auf die Beine helfen.1,5 ist zur Zeit eine kleine Untestützung die aber auch wieder keine ist.Mal sehen was wird.Ich bin für ca 1,85 Euro rein mit einer sehr kleinen Position.

Travelers` Diseases



Johns Hopkins University Is Test Site of Vaccine for Illnesses From Contaminated Food, Water

GAITHERSBURG, Md., Dec. 18 /PRNewswire/ -- Antex Biologics Inc. (Amex: ANX - news) today announced that it has begun a Phase I human clinical trial for the second component of its combination ACTIVAX vaccine to prevent travelers` diseases caused by the consumption of contaminated food and water. The trial, to be carried out at the Johns Hopkins University Vaccine Testing Unit in Baltimore, is designed to test the safety and immunogenicity of a vaccine against Shigella sonnei infection. The vaccine has been developed using the Company`s proprietary Nutriment Signal Transduction (NST) technology. There are currently no vaccines on the market for travelers` diseases, which are responsible for more than three million deaths a year worldwide.

Diseases caused by the consumption of contaminated food and water are the most prevalent illnesses afflicting travelers and are serious problems for military troops deployed overseas. Enteric bacteria, including Campylobacter jejuni, Shigella and E. coli (ETEC), are the most common causes of these diseases, which can include gastritis, acute diarrhea, high fever, dehydration, severe dysentery and often death.

ACTIVAX is a multi-component vaccine designed to prevent and eradicate travelers` diseases caused by Campylobacter jejuni, Shigella and E. coli (ETEC) bacteria. Each of the vaccine components may also be developed as individual vaccines. The component of ACTIVAX that addresses Campylobacter jejuni has completed Phase I and II human clinical trials and is proceeding towards product commercialization, with an additional Phase II trial planned for 2002. The Shigella sonnei component has completed all required pre- clinical studies and analyses and has proven to be safe and effective. The Phase I trial should be completed in late 2002 or early 2003.

``Taking Shigella sonnei, our second ACTIVAX component, into clinical trials represents a significant milestone for the company and is another validation of the robustness of our NST development platform,`` said Antex Chairman, President and Chief Executive Officer Vic Esposito. ``Based on our success with Campylobacter jejuni, we anticipate the Shigella sonnei component of ACTIVAX to demonstrate a similar safety and immunogenicity profile.``

International public health officials estimate that Campylobacter jejuni alone causes 400 to 500 million cases of diarrhea worldwide each year, and it is the number one food-borne pathogen in the U.S. E. coli (ETEC) is estimated to cause more than 600 million cases of mild to severe diarrhea annually. Shigella is estimated to add more than 200 million cases annually worldwide and is an unusually virulent bacterium that causes endemic or epidemic dysentery with high death rates. Together, these bacteria are responsible for more than one billion cases of travelers` diseases each year. Infections occur most frequently in overcrowded areas with poor sanitation and sub- standard hygiene, and can be transmitted through person-to-person contact and through contaminated food and unsafe water supplies. There are no vaccines on the market against travelers` diseases.

Bis dann Euer Donkosak-Grischka

[Donkosak]

Hallo an Alle

Es dauert ganz schön lange bis eine News kommt. Aber hier ist endlich wieder was .Macht Euch selbst ein Bild,für mich ist sie eine Bestätigung die Aktie weiter zu halten.

Reed Army Institute of Research



Walter Reed Army Institute for Research to Produce STD and Enteric Vaccines

GAITHERSBURG, Md., Jan. 15 /PRNewswire-FirstCall/ -- Antex Biologics Inc. (Amex: ANX) announced that it has extended its product development agreement with the Walter Reed Army Institute for Research (WRAIR) bioproduction facility through the end of 2003. Antex, the Army`s longest standing biologics manufacturing client, will use the Army`s Silver Spring, MD, GMP-compliant production facility to manufacture clinical trial materials. The collaboration will include manufacturing seed banks and Phase I clinical trial material for the TRACVAX vaccine against Chlamydia trachomatis, and Phase II clinical trial material for the HELIVAX vaccine against Helicobacter pylori, as well as material for other vaccines as required.

"WRAIR is an excellent partner, helping Antex meet our clinical trial production needs," said Dr Alan Liss, Vice President of Product Development. "We look forward to expanding this relationship as we continue to advance our vaccine products through the development process."

TRACVAX is a vaccine designed to prevent diseases caused by the Chlamydia trachomatis bacteria, and is produced using Antex`s proprietary antigen receptor technology. Company scientists have identified a novel protein that has been evaluated as a recombinant subunit vaccine in preclinical animal models. Antex recently initiated its Phase I human clinical trial on TRACVAX and expects to enroll its first patients in mid-2002.

Chlamydia trachomatis is a sexually transmitted disease that often leads to Pelvic Inflammatory Disease, infertility and blindness. It is the leading cause of infertility and blindness in many countries, including the United States where annually over 20,000 women diagnosed as infertile are so as a direct result of Chlamydia infection. While it is estimated that 25 percent of men and 75 percent of women diagnosed with Chlamydia are asymptomatic, there are still over four million cases of Chlamydia trachomatis reported in the United States each year, with an estimated annual treatment cost exceeding $8 billion.

HELIVAX is an orally administered vaccine designed to prevent gastrointestinal cancers and ulcers by treating infections of the Helicobacter pylori bacteria. Antex completed a second Phase I human clinical trial on HELIVAX earlier this year, and has recently initiated its Phase II human clinical trial and expects to enroll its first patients in this trial in mid-2002.

Heliobacter pylori is believed to infect nearly 50 percent of the population in the United States, with a significantly higher percentage rate worldwide; it has been determined to cause approximately 90 percent of gastric and duodenal ulcers and is a leading cause of gastric cancer.

Auf weitere gute Nachrichten Euer Donkosak-Grischka

[Donkosak]

Was für ein Interesse an dieser Aktie,bin überrascht

So noch was Neues

Antex shares up 11 pct on news of anthrax trials
LOS ANGELES, Feb 7 (Reuters) - Shares of Antex Biologics Inc. (AMEX:ANX - news) rose 11 percent on Thursday after the maker of infectious disease treatments said the U.S. Army will test its experimental antibiotics to see if they are effective against anthrax.

Shares of the Gaithersburg, Maryland-based company rose 15 cents to close at $1.50 on the American Stock Exchange.

Under the agreement, the Army will test Antex`s lead antibiotic and other compounds to see if they are potent against fighting anthrax infections and diseases caused by the anthrax bacteria.

Antex said its lead experimental antibiotic, known as AP158, is a novel therapeutic initially targeted for skin and soft tissue infections, including diabetic foot ulcers and other types of infection that may have become resistant to standard antibiotics such as those in the penicillin family.

Animal tests have shown that AP158 is effective against a bacteria that is genetically similar to anthrax, Antex said.

Vic Esposito, the company`s chief executive, said AP158 has a mechanism of action that is different from penicillin or newer antibiotics, such as Cipro, the Bayer AG antibiotic currently viewed as the gold standard for treating anthrax.

``With the wide use of Cipro, you start running the risk of resistance developing,`` Esposito said.

Bis denne Euer Donkosak-Grischka

[Donkosak]

Hallo und was kleines zum Lesen

Antex Biologics Presents at 14th Annual Roth Capital Partners Growth Stock Conference
GAITHERSBURG, Md., Feb. 19 /PRNewswire-FirstCall/ -- Antex Biologics (Amex: ANX - news) is a biopharmaceutical company committed to developing new products for chronic bacterial infections and related diseases. The Company is currently focused on the development of vaccines and antibiotics for enteric, sexually transmitted and respiratory infections. Antex plans to have six products in clinical trials in 2002 and maintains strategic alliances with GlaxoSmithKline, Aventis Pasteur, and the U.S. Department of Defense.

HELIVAX(TM), a vaccine for the prevention and eradication of Helicobacter pylori, the causative agent for ulcer disease and stomach cancer has completed Phase IA and IB human clinical trials. These trials showed the vaccine to be safe and, as expected, based on preclinical studies, HELIVAX generated significant immune responses. A Phase II human clinical trial is scheduled for 2002.

ACTIVAX(TM) is a multi-component vaccine to protect travelers against the leading causes of gastritis and diarrhea caused by contaminated food and water. A Phase IIA clinical trial of the Campylobacter jejuni component of ACTIVAX, conducted in cooperation with the U.S. Department of Defense, showed significant immune responses that correlated with protection against disease. A Phase IIB trial is currently being conducted. Campylobacter is now the number one food borne pathogen in the United States. A Phase I human clinical trial for the Shigella component of the combination ACTIVAX vaccine is now being conducted at the Johns Hopkins University. The third component of this vaccine, enterotoxigenic E. coli is also in clinical evaluation. Preclinical animal studies demonstrated protection against infections and diseases of the three pathogens.

TRACVAX(TM) is a vaccine for Chlamydia trachomatis, the world`s leading sexually transmitted infection. Chlamydia, often an asymptomatic infection, can lead to inflammation, infertility, arthritis and blindness if not treated. Antex, a leader in Chlamydia research, has developed a novel vaccine that shows greater than 85 percent protection in preclinical studies. A human clinical trial is scheduled during 2002.

AP158 is a novel drug for treating various infections of skin and soft tissue. Preclinical evaluation has demonstrated AP158 to be nontoxic and to be effective in treating antibiotic resistant bacteria. Antex through its wholly-owned subsidiary, AntexPharma, has developed three series of new antibiotic compounds with novel mechanisms of action. Results have identified lead compounds which are effective against a broad spectrum of important pathogens and compounds that are monospecific for certain pathogens. In addition, the Company is working with the U.S. Army to evaluate these new compounds against anthrax. A Phase I human clinical trial will begin in 2002.

RESPIRATORY VACCINES. Antex has partnered with GlaxoSmithKline and Aventis Pasteur for the development of pediatric respiratory vaccines. Aventis Pasteur is in Phase II human clinical trials for Antex`s novel pediatric middle ear infection vaccine. GlaxoSmithKline is in preclinical evaluation of a number of respiratory vaccine candidates.

Antex continues to build shareholder value by: (i) focusing on bacterial infections, (ii) maintaining a balanced product portfolio, (iii) leveraging resources through strategic alliances, and (iv) achieving profitability by product sales. These strategies are driven by a very broad and patented technology platform.

Bis dann

[Donkosak]

Damit es Vollständig ist

To Begin Clinical Dosing For Two Vaccines To Prevent Travelers` Diseases



Campylobacter and Shigella Human Clinical Trials Underway

GAITHERSBURG, Md., March 14 /PRNewswire-FirstCall/ -- Antex Biologics Inc. (Amex: ANX) today announced that it will begin dosing patients for two of the components of its combination ACTIVAX(TM) vaccine to prevent Travelers` Diseases. The first component, an inactivated whole cell vaccine for Campylobacter jejuni, has completed patient enrollment and will begin dosing patients at the Naval Medical Research Center at the Walter Reed Army Institute of Medical Research in Forest Glen, Maryland next week. The second component, an inactivated whole cell vaccine for Shigella sonnei, anticipates completing enrollment by the end of March and dosing patients at the Johns Hopkins Vaccine Testing Unit in Baltimore beginning on the first of April.

Diseases caused by the consumption of contaminated food and water are the most prevalent illnesses afflicting travelers and are serious problems for military troops deployed overseas. Enteric bacteria, including Campylobacter jejuni, Shigella spp. and enterotoxigenic E. coli (ETEC), are the most common causes of these diseases, which can include gastritis, acute diarrhea, high fever, dehydration, severe dysentery and often death.

ACTIVAX is a multi-component vaccine designed to prevent and eradicate travelers` diseases caused by Campylobacter jejuni, Shigella and ETEC bacteria. The Company is also developing each of the vaccine components as potential individual pathogen-specific vaccines. The components of ACTIVAX that address infections caused by Campylobacter jejuni and Shigella sonnei have been developed using the Company`s proprietary Nutriment Signal Transduction technology.

Donkosak

[Donkosak]

Hallo und noch einen schönen Vatertag

Hier was nicht ganz so neues 3 Tage alt

Antex Lead Antibiotic Makes Major Advances; First Human Trial Scheduled for Later This Year
GAITHERSBURG, Md., May 8 /PRNewswire-FirstCall/ -- Antex Pharma Inc., a wholly owned subsidiary of Antex Biologics Inc. (Amex: ANX - news), today announced major advances for AP-158, its lead antibiotic compound. AP-158 is a novel chemical entity with a unique mechanism of action distinct from that of any known antibiotic. During the past 18 months in its Maryland laboratories, Antex has:


-- proven AP-158 to have potent in vitro activity against clinically
important bacteria including: Staphylococcus aureus, Staphylococcus
epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes,
E. coli, Enterococcus faecalis, Corynebacterium diphtheria, Moraxella
catarrhalis, Haemophilus influenzae and Bacillus cereus;

-- filed provisional U.S. patent applications on a novel series of
chemical compounds, claiming composition of matter, methods of
production, and use of the compounds as anti-infectives and
disinfectants, including AP-158 for the initial application as a
topical antibiotic;

-- evaluated and confirmed the efficacy of AP-158 as a topical
antibiotic in various in vivo infectious wound models, including the
leading hospital-acquired infection -- Methicillin Resistant
Staphylococcus aureus (MRSA);

-- performed genetic toxicology studies, demonstrating the compound to
be non-mutagenic and non-clastogenic;

-- demonstrated in pre-clinical studies that AP-158 does not produce
dermal irritancy in animals;

-- begun acute toxicology and pharmacology studies in two species;

-- begun collaborating with the U.S. Army to evaluate AP-158 against
Bacillus anthracis, or anthrax;

-- developed an effective formulation suitable for human clinical
applications; and

-- manufactured a cGMP batch of AP-158 in preparation for a Phase 1
clinical trial in 2002.


In 1999, Antex scientists discovered and synthesized four series of novel structures, giving the Company a proprietary position of over ten million new chemical entities. The compounds, including AP-158, were derived using Antex`s "targeted molecular diversity" approach, which integrates structure- based rational drug design with combinatorial chemistry to design and optimize a diverse compound library.

AP-158 initially is being developed to treat serious infections caused by MRSA, as well as Vancomycin Resistant Enterococci (VRE) and other organisms that are becoming increasingly resistant to available antibiotics. Mortality rates and hospital "length-of-stay" rates are estimated to double for patients with VRE and MSRA infections. Hospital-acquired infections caused by these and other resistant bacteria cost an estimated $30 billion annually, according to the National Institutes of Health.

"We are extremely excited about the progress we have made with our novel therapeutic products, especially AP-158," said Vic Esposito, Antex`s President and Chief Executive Officer. "AP-158 will address unmet clinical needs of antibiotic resistance and newly emerging bacterial diseases, and may play an important role in the war against bio-terrorism."

Bis denne Donkosak

[Donkosak]

Nachtrag

Wer Vancomycin schlägt der kann.............


Donkosak

[Donkosak]

Hallo an Alle

Antex Presents Pre-Clinical Chlamydia Results At American Society of Microbiologists Conference
First Human Clinical Trial Planned for Later This Year
GAITHERSBURG, Md., May 21 /PRNewswire-FirstCall/ -- Antex Biologics Inc. (Amex: ANX - News) announced today that it will present at the annual meeting of the American Society of Microbiologists held in Salt Lake City later this week. The presentation will outline immunogenicity and protective efficacy results obtained from a "super-family" of nine proteins encoded by the intracellular pathogen Chlamydia trachomatis. This super-family of proteins is predicted to be membrane associated and possibly surfaced exposed.

W. James Jackson, PhD., the Company`s Vice President of Research, will report that a team of Antex scientists have found that recombinant forms of these polymorphic membrane proteins are highly conserved among different Chlamydia serovars, protect animals against Chlamydia induced infertility, and confer heterotypic cross protection. Based on antibody responses among individual animals immunized mucosally, and the resultant cytokine release and antibody isotype profiles, the protection afforded appears to correlate with both Th1 (cellular) and Th2 (humoral) type immune responses.

Antex plans to initiate a Phase I human clinical trial for its TRACVAX recombinant subunit vaccine against Chlamydia trachomatis later this year. TRACVAX is produced using Antex`s proprietary antigen receptor technology.

Chlamydia trachomatis is a sexually transmitted disease that often leads to Pelvic Inflammatory Disease, infertility and blindness. It is the leading cause of infertility and blindness in many countries, including the United States where annually over 20,000 women diagnosed as infertile are so as a direct result of Chlamydia infection. While its is estimated that 25 percent of men and 75 percent of women diagnosed with Chlamydia are asymptomatic, there are still over four million cases of Chlamydia trachomatis reported in the United States each year, with an estimated annual treatment cost exceeding $8 billion

Bis denne Donkosak

[Donkosak]

Na warum wohl der kurze Anstieg heute

Antex Responds to Defense Department Request To Submit White Paper on Lead Antibiotic
U.S. Military Sees Potential in Novel Antibiotic Compound as Bio-Terrorism Countermeasure
GAITHERSBURG, Md., May 28 /PRNewswire-FirstCall/ -- Antex Biologics Inc. (Amex: ANX - News) announced today that it has responded to a request from the U.S. Under Secretary of Defense for Acquisition, Technology and Logistics to submit a scientific "white paper" describing the potential efficacy of its novel antibiotic compound, AP 158, as both a therapeutic drug and a decontaminating agent in combating bio-terrorism. The white paper could lead to a multi-year contract for the development of Antex`s novel compound(s) as an effective bio-terrorism antibiotic resource to fight anthrax infections and other diseases.

AP 158 is a novel chemical entity with potent, bactericidal activity against a large number of clinically significant pathogens including Bacillus cereus, a sporeforming bacterial pathogen genetically similar to Bacillus anthracis (anthrax). This new compound has a unique mechanism of action distinct from that of any known antibiotic and is expected to be active against beta-lactam, quinolone, or tetracycline resistant strains of anthrax. Because this compound exerts its effect at the level of the cell membrane, it may also inhibit anthrax spores from becoming vegetative cells.

Earlier this year, Antex announced that the U.S. Army Medical Research Institute of Infectious Diseases agreed to perform various tests and laboratory assays on AP 158 (along with several other of the Company`s novel antibiotic compounds) to determine if Antex`s lead antibiotic is potent against fighting anthrax infections and related diseases. The Company expects the Army to complete its testing within the next few weeks.

As a topically applied antibiotic, AP 158 is initially being targeted for skin and soft tissue infections, designed to treat serious infections caused by Vancomycin Resistant Enterococci (VRE), Methicillin Resistant Staphylococcus aureus (MSRA) and other organisms that are becoming increasingly resistant to available antibiotics.

wird Vancomycin bald keine Rolle mehr spielen

Bis denn Donkosak

[Donkosak]

Schönene Nachmittag noch

Was Neues nach den netten Kursverlußten der letzten Tage

GAITHERSBURG, Md., Aug. 7 /PRNewswire-FirstCall/ -- Antex Biologics Inc. (Amex: ANX - News) today announced the initial results of the U.S. Army`s tests on AP 158 and several other novel compounds, as potential drugs to treat anthrax. These laboratory tests showed the compounds to be active against the bacteria Bacillus anthracis and provide the basis for further assessment of the compounds` potential for treating anthrax disease. ADVERTISEMENT



pplication, AP 158`s initial commercial application as a topically applied antibiotic is targeted for skin and soft tissue infections to treat serious infections caused by Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococci (VRE), and the newly identified Vancomycin Resistant Staphylococcus aureus (VRSA). The Company also plans to develop the drug in other formulations for use in ophthalmic, oral and systemic applications. The Centers for Disease Control and Prevention recently reported that resistant forms of Staphylococcus aureus, including MRSA and VRSA, are becoming more and more of a national health care problem. Mortality rates and hospital "length-of-stay" rates are estimated to double for patients with resistant Staphylococcus aureus infections. The National Institutes of Health estimate hospital-acquired infections caused by these and other resistant bacteria cost an estimated $30 billion annually in the U.S. alone.

Bis denne vielleicht hilft es ja dem Kurs